OGENORAGENICS INC

NYSE oragenics.com


$ 0.94 $ -0.08 (-7.84 %)    

Tuesday, 20-Aug-2024 15:35:17 EDT
QQQ $ 480.15 $ -1.15 (-0.24 %)
DIA $ 408.54 $ -0.35 (-0.09 %)
SPY $ 558.65 $ -0.51 (-0.09 %)
TLT $ 98.68 $ 0.38 (0.39 %)
GLD $ 232.46 $ -1.26 (-0.54 %)
$ 0.9305
$ 0.98
$ 0.88 x 100
-- x --
$ 0.94 - $ 0.98
$ 0.86 - $ 7.74
353,178
na
4.62M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 04-17-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-24-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-03-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 03-04-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-13-2019 03-31-2019 10-Q
23 03-29-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-13-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 02-16-2018 12-31-2017 10-K
28 10-31-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 02-27-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-15-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 02-27-2015 12-31-2014 10-K
40 11-03-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oragenics-provides-update-on-onp-002-intended-to-treat-concussion-and-receives-notice-of-non-compliance-with-nyse-american-listing-standards

Oragenics, Inc. (NYSE:OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the...

 oragenics-shows-onp-002-for-treatment-of-concussions-stable-across-temperature-range

• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion

 why-oragenics-ogen-shares-are-falling

Oragenics shares are trading lower by 21% during Tuesday's session. The company announced pricing of its public offering.

 oragenics-partners-with-avance-clinical-for-phase-ii-concussion-trial-in-australia

Oragenics, Inc. (NYSE:OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today an...

 oragenics-inc-files-10k-and-provides-company-update

Oragenics, Inc. (the "Company") (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the...

 sp-500-edges-lower-adt-posts-upbeat-earnings

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow t...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION